Advertisement

Japanese Journal of Ophthalmology

, Volume 53, Issue 3, pp 286–287 | Cite as

Treating refractory scleritis with infliximab

  • Seong Joon Ahn
  • Joo Youn Oh
  • Mee Kum Kim
  • Won Ryang WeeEmail author
Letters

Key Words

infliximab scleritis tumor necrosis factor α 

References

  1. 1.
    Mychalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep 2008;8:339–447.CrossRefGoogle Scholar
  2. 2.
    Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895–900.CrossRefPubMedGoogle Scholar
  3. 3.
    Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317–2323.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–257.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society (JOS) 2009

Authors and Affiliations

  • Seong Joon Ahn
    • 1
    • 2
  • Joo Youn Oh
    • 1
    • 2
  • Mee Kum Kim
    • 1
    • 2
  • Won Ryang Wee
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of OphthalmologySeoul National University College of MedicineSeoulKorea
  2. 2.Seoul Artificial Eye CenterSeoul National University Hospital Clinical Research InstituteSeoulKorea
  3. 3.Department of OphthalmologySeoul National University College of MedicineSeoulKorea

Personalised recommendations